Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2015
2015 News
Press Release
IR News
Information
Press Release
11.04.2015
NICE recommends the use of IKERVIS® in England for the treatment of severe keratitis in adult patients with dry eye disease
11.04.2015
Santen Announces Financial Result for the Second Quarter ended September 30, 2015
11.04.2015
Santen Reports Consolidated Performance For the First Half of FY2015
09.01.2015
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
08.25.2015
Santen Announces Approval of TAPROS for the Treatment of Open-Angle Glaucoma and Ocular Hypertension in China
Press Release
IR News
11.04.2015
NICE recommends the use of IKERVIS® in England for the treatment of severe keratitis in adult patients with dry eye disease
11.04.2015
Santen Announces Financial Result for the Second Quarter ended September 30, 2015
11.04.2015
Santen Reports Consolidated Performance For the First Half of FY2015
11.04.2015
NICE recommends the use of IKERVIS in England for the treatment of severe keratitis in adult patients with dry eye disease
09.01.2015
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
IR News
Information
12.10.2015
Santen Announces Basic Policy On Corporate Governance
12.08.2015
Santen has received the "IT General Award"
09.14.2015
Meeting Video and Presentation Material on R&D meeting
06.01.2015
Convocation Notice of the 103rd Annual General Meeting of Shareholder
02.06.2015
Telephone conference on the Financial Result of the 3rd Quarter of FY2014
Information
News Archive
